Completed

A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

adjuvant therapy

+ conventional surgery

+ brachytherapy

ProcedureRadiation
Who is being recruted

Urogenital Diseases+9

+ Genital Diseases

+ Female Urogenital Diseases and Pregnancy Complications

See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: April 1998
See protocol details

Summary

Principal SponsorMedical Research Council
Last updated: December 19, 2013
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 1998

Actual date on which the first participant was enrolled.

OBJECTIVES: Compare the effects of conventional surgery alone and conventional surgery plus lymphadenectomy in patients with endometrial cancer preoperatively thought to be confined to the uterine corpus. Determine the effect of postoperative adjuvant external beam radiotherapy on quality of life and survival of a subset of these patients at high risk of relapse and with no macroscopic disease after surgery. OUTLINE: This is a randomized, multicenter study. Patients are randomized in both the surgery and radiotherapy segments of the study. Surgery: Patients are randomized to 1 of 2 surgery arms. Arm I: Patients undergo conventional surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy). Arm II: Patients undergo conventional surgery as in arm I followed by lymphadenectomy with systematic dissection of the iliac and obturator nodes. Radiotherapy: Patients at high risk of relapse who have no postoperative macroscopic disease are randomized to 1 of 2 radiotherapy arms. (Patients may enter the radiotherapy randomization after surgery off study.) Arm I: Patients receive in 20-25 fractions of external beam radiotherapy (total dose of 40-46 Gy) over 4-5 weeks. Arm II: Patients receive no external beam radiotherapy. NOTE: Some patients receive vault brachytherapy regardless of radiotherapy randomization. Quality of life is assessed before therapy and at 2 and 5 years after therapy. Patients are followed every 3 months for 1 year and then every 6 months for 1 year. PROJECTED ACCRUAL: A minimum of 1400 patients will be accrued for the surgical component of this study and at least 900 patients (including additional patients not participating in the surgical component of this study) will be accrued for the radiotherapy component of this study.

NCT00003749
Principal SponsorMedical Research Council
Last updated: December 19, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

2300 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Neoplasms, FemaleNeoplasmsNeoplasms by SiteUrogenital NeoplasmsUterine DiseasesUterine NeoplasmsFemale Urogenital DiseasesEndometrial Neoplasms

Criteria

DISEASE CHARACTERISTICS: Surgical randomization: Histologically confirmed endometrial carcinoma Disease thought preoperatively to be confined to the uterine corpus Radiotherapy randomization: Must have disease determined postoperatively to be confined to the uterine corpus, irrespective of pelvic node status No cervical stroma invasion (stage IIB) Must be macroscopically free of disease (no positive para-aortic nodes) Must have high-risk disease defined as one or more of the following: Grade 3 (poorly differentiated) Invasion to the outer half of the myometrium (stage IC) Serous papillary or clear cell type Stage IIA (endocervical glandular involvement) PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other prior or concurrent malignancy likely to interfere with protocol treatment or comparisons Surgical randomization: Must be fit to undergo lymphadenectomy and external beam radiotherapy Radiotherapy randomizations: Must be fit to receive external beam radiotherapy PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

Medical Research Council Clinical Trials Unit

London, United KingdomOpen Medical Research Council Clinical Trials Unit in Google Maps

Royal Marsden NHS FoundationTrust - London

London, United Kingdom

St. Mary's Hospital

Manchester, United Kingdom
Completed3 Study Centers